Reports claim American Airlines is mulling stake in Chinese airline
Most Active mover Update on Nektar Therapeutics (NASDAQ:NKTR)
21 March 2017, 12:34 | Austin Hogan
Alexander Gatsenko | E+ | Getty Images
Nektar Therapeutics (NASDAQ:NKTR) reported its EPS in the last quarter as $-0.28/Share Lagging the analyst estimate of $-0.26/Share by the difference of $-0.02.
This recommendation lands on a scale between 1 and 5. Analysts predict that Nektar Therapeutics will post ($1.35) EPS for the current year.
03/02/2017 - Nektar Therapeutics had its "buy" rating reiterated by analysts at Aegis Capital.
As for next steps, Nektar stated on its last conference call with investors that it plans to out-license the drug to "a company that has a strong presence and long-term commitment in the pain market".
At time of writing this, the stock jumped 22.58 percent. In the last five years, the company's full-year sales growth remained over 18.30% a year on average and the company's earnings per share moved up by an average rate of 1.50%. BTIG Research began coverage on shares of Nektar Therapeutics in a research report on Friday, January 6th. A recent bid put the stock price near $19.85. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp increased its position in Nektar Therapeutics by 133.9% in the third quarter.
Britain to trigger Brexit March 29
However, the European Council wants to sort out Britain's "divorce bill" from the bloc before any future relationship is agreed. Barnier has said that he expects a deal to be agreed in 2018 and ratified in 2019.
Robert Downey Jr. to star in new Dr. Dolittle film
Joe Roth and Jeff Kirschenbaum are producing the film for their Roth/Kirschenbaum Films, alongside Susan Downey for Team Downey. He will reprise the role in the upcoming Spider-Man: Homecoming and Avengers: Infinity War .
09/17/2014 - Nektar Therapeutics had its "underperform" rating reiterated by analysts at Bank of America Merrill Lynch. The stock has a 50 day moving average price of $13.78 and a 200-day moving average price of $14.35. For the past month, Nektar Therapeutics's stock has been 13.14%, 27.26% for the last quarter, -19.48% for the past six months and 25.81% for the past 52 weeks.
Shares of Nektar Therapeutics (NASDAQ:NKTR) have shifted north recently, touching a new 52-week high.
Nektar Therapeutics is a biopharmaceutical company. Considering the earnings reaction history, The Company has topped 83% percentage. Its pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. In a human abuse potential study the highest analgesic dose of NKTR-181 was barely distinguishable from placebo in terms of drug-liking and euphoria. Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection).
Receive Nektar Therapeutics News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics with MarketBeat.com's FREE daily email newsletter.
After poll debacle, Irom in Kerala to live among tribals
For the people on the ground, however, it falls much below the day-to-day struggles of bandh and blockade and lack of development. While the PRJA had fielded only three candidates, including Sharmila, it did it best to fend off predictions of a massive loss.
Surface Book 2 is coming, could be announced next month
Reports of poor Surface Book sales had analysts questioning whether MSFT would even bother releasing a Surface Book 2. About Making Comments on our Site: Patently Apple reserves the right to post, dismiss or edit any comments.
Russian Federation claims: No evidence of collusion - Nunes
He declined to speculate on how long it would take to conduct the investigation, but suggested that it wasn't nearing completion. National Security Agency, Admiral Mike Rogers , told Monday's hearing that the allegation had strained relations with London.
Goebel flying high with Nicki Minaj
All of this comes ahead of Nicki's next album, the follow-up to 2014's The Pinkprint , which is expected this year. Earlier this month, Nicki addressed her rival Remy Ma by predicting and boasting about this week's news.
United Kingdom to begin Brexit process on March 29
The move comes nine months after Britain voted 51.9 percent to 48.1 percent in favour of Brexit in a referendum on 23 June, 2016. Her first stop was Wales, and she was also expected to visit sites in Scotland, Northern Ireland and England in the coming days.